Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRL201805 in moderately to severely active rheumatoid arthritis
2021-005771-39Phase 2Terminated
- Sponsor
- Revolo Biotherapeutics
- Start
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing IRL201805 with Placebo (2 arms). Primary endpoint: Change from baseline in Disease Activity Score at Week 12. Started Jun 2022; status: terminated.
02
Drugs
IRL201805
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2021-005771-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005771-39.